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Prospective cardiovascular magnetic
resonance imaging in adults with Alström
syndrome: silent progression of diffuse
interstitial fibrosis
Shanat Baig1,2, Rory Dowd3, Nicola C. Edwards2,3, James Hodson4, Larissa Fabritz2,3, Ravi Vijapurapu1,2,
Boyang Liu1,2, Tarekegn Geberhiwot1,5 and Richard P. Steeds2,3,6*
Abstract
Background: Alström syndrome (ALMS) is a rare ciliopathy characterised by early onset insulin resistance, obesity,
and dyslipidaemia and is a model for diseases that have huge social, health and economic impact. Cardiomyopathy
develops in the majority, with high rates of morbidity and mortality, the definitive features of which are coarse
replacement fibrosis and diffuse myocardial fibrosis (DIF). The pathogenesis of heart failure is thought to involve
fibroblast accumulation and expansion of the extracellular matrix with excess protein deposition, leading to
distorted organ architecture and impaired contractile function. Consecutive adults with genetically proven ALMS
attending the National Centre for Rare Disease in Birmingham, England were studied. All patients underwent serial
CMR, echocardiography and venous blood sampling, with computed tomography coronary angiography (CTCA)
performed to assess severity of CAD. The aims of this study were: 1) to evaluate changes over time in DIF by
cardiovascular magnetic resonance tissue characterization in ALMS; 2) to examine whether changes in DIF are
associated with alteration in systolic or diastolic function; and 3) to evaluate the frequency and severity of coronary
artery disease as a confounder for progression of ischaemic versus non-ischaemic fibrosis.
Results: In total, 30/32 adults (63% male; 67% White British) participated. The median age at first scan was 21.3
years (interquartile range: 19.0–32.6) and participants were followed for a maximum of 67 months. Only 4 patients
had significant coronary artery stenosis on post-mortem, invasive coronary angiography or CTCA. Mid short axis
myocardial T1 times, myocardial extracellular volume, and left ventricular mass increased significantly over time, by
an average of 21.8 ms (95% CI 17.4–26.1; p < 0.001), 1.1 percentage points (0.6–1.6, p < 0.001), and 2.8 g/m2 (1.9–3.7;
p < 0.001) per year, respectively. These changes were not associated with significant deterioration in myocardial
structure or function.
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Conclusions: This is the first comprehensive prospective study demonstrating progression of DIF in ALMS over
time, although no structural or functional consequences were noted within a median three and a half years’ follow
up. Further study is warranted to define whether DIF is a by-stander or the driver to impaired contractile function,
heart failure and death.
Keywords: Alström syndrome, Cardiovascular magnetic resonance, Diffuse interstitial fibrosis, Progression,
Extracellular volume, Ischaemic heart disease
Introduction
Alström syndrome (ALMS) is a rare autosomal recessive
cardiomyopathy (OMIM 203800) characterised by multi-
organ disease. Infantile cardiomyopathy and retinal cone
rod dystrophy are the earliest and most frequent mani-
festations of the syndrome. The most severe and often
lethal complication of ALMS is heart failure due to car-
diomyopathy [1]. Cardiomyopathy affects up to 65% of
adolescents and adults, with high rates of morbidity and
mortality [2]. Both the quality and length of life are re-
duced in adults with ALMS, and few survive beyond the
age of 50 [2]. Autopsy data have demonstrated replace-
ment myocardial fibrosis in non-coronary artery pat-
terns, and diffuse interstitial fibrosis (DIF) has been
detected on cardiovascular magnetic resonance (CMR)
by elevation in T1 relaxation [3] and increased extracel-
lular volume (ECV) in cross-sectional studies of ALMS
[4]. These changes were associated with sub-clinical im-
pairment of left ventricular (LV) function, assessed
through change in myocardial strain. In many cardiovas-
cular diseases, it has been postulated that the develop-
ment of DIF over time may be a driver of abnormal
myocardial deformation and diastolic dysfunction, lead-
ing ultimately to systolic heart failure [5]. While ALMS
is rare, it offers a model of myocardial disease in which
disease progression may be rapid, although serial assess-
ment has not previously been performed.
Given the frequency of obesity, insulin resistance and
metabolic syndrome in ALMS, ischaemic heart disease
may well represent a potential confounder to increased
T1 relaxation times and ECV [6]. Despite the high bur-
den of CV risk factors, reported cases of coronary artery
disease (CAD) are rare and data have been limited [7].
Moreover, defining serial changes in T1 and ECV rela-
tive to the frequency of coronary disease is important on
a clinical basis, since primary and secondary treatment
strategies differ. Therefore, the aims of this study were:
1) to evaluate changes in DIF over time by CMR tissue
characterization in adults with ALMS; 2) to examine
whether changes in DIF could be associated with alter-
ation in systolic or diastolic function; and 3) to evaluate
the frequency and severity of coronary artery disease as




Between March 2012 and January 2018, 32 consecutive
adults with genetically proven ALMS attending the Na-
tional Centre for Alstrom syndrome at the Queen Eliza-
beth Hospital Birmingham, United Kingdom (UK) were
evaluated as part of standard clinical care. The clinic is
unusual in that it is patient-centred, run in association
with the charity Alström Syndrome UK and involves
physicians from different specialties, nurses and relevant
professions allied to medicine, forming a truly multidis-
ciplinary team (MDT). Patients attend for 2 days and in
this time, undergo all their relevant investigations, and
are seen by all members of the MDT. At the first and
subsequent visit, patients underwent annual disease
monitoring following a standardized clinical protocol, in-
cluding: biochemistry, echocardiography, and CMR. This
was an observational, retrospective audit, utilizing exist-
ing data collected as part of clinical service. It was ap-
proved by local clinical governance committees
(CARMS-15674) and conformed to the principles of
Good Clinical Practice guidelines. Patients were eligible
for inclusion in this audit if they were ≥ 16 years of age;
had a genetically confirmed diagnosis of ALMS; and had
been followed up in the service for a minimum of 1 year.
Patients were excluded if they had an absolute contra-
indication to CMR (1 patient with implantable cardio
defibrillator) or a relative contra-indication for the study
(1 patient was on a research drug trial). Otherwise, all
adult patients in the service were included. Serial CMR
and single computed tomography coronary angiography
(CTCA) were included as standard for ALMS patients.
Annual CMR was instituted from the start of the clinical
service, while CTCA was introduced soon after the inci-
dental finding of an occluded right coronary artery in an
asymptomatic 38 year old male.
Investigations
Blood markers
Venous blood samples were collected for haematology,
biochemistry, and lipid profiles. Serum N-terminal pro B
natriuretic peptide (NT-proBNP, ng/L) was measured by
sandwich immunoassay with magnetic particle separ-
ation and chemiluminescent detection on an E170
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analyser (Roche Diagnostics, Burgess Hill, United King-
dom) with a lower limit of detection of 0.6 pmol/L. Dys-
lipidaemia was defined as fasting cholesterol > 5mmol/L
and/or triglycerides > 1.7 mmol/L.
Echocardiography
Resting transthoracic echocardiography (TTE; ie33, Phil-
lips) was performed by an accredited sonographer ac-
cording to the British Society of Echocardiography
minimum dataset [8]. Diastolic function was graded by
an experienced cardiologist specialising in echocardiog-
raphy (RPS) according to current guidelines [9].
Cardiac magnetic resonance imaging
Contrast enhanced CMR (1.5 T Avanto, Siemens Health-
care, Erlangen, Germany) was performed in-line with
standard protocols to obtain LV and right ventricular
(RV) dimensions, volumes, and mass on a bi-annual
basis [10]. A steady-state free precession, single breath
hold modified Look-Locker inversion recovery (MOLLI)
sequence was used for T1 mapping in the basal and mid
left ventricular short axis levels and the horizontal long-
axis, before and 15–20min after administration of
gadolinium-based contrast agent (GBCA) [10]. Average
scan parameters: 8 mm slice with a 192 read-out matrix,
6/8 phase partial Fourier with 81% phase resolution,
field-of-view 320 × 320 mm2, repetition time 2.4 ms, echo
time 1.01 ms, 11 phases [3, 3, 5 scheme], total breath
hold 17 R-R intervals [11]. LGE imaging was performed
7–10 min after 0.15 mmol/kg of GBCA given as a bolus
(Gadovist, Bayer Health Care) using phase sensitive in-
version recovery. Analysis of volumes, mass, and func-
tion was performed off-line using Cvi42 software (Circle
Cardiovascular Imaging, Calgary, Canada) according to
the Society for CMR guidelines for reporting, with pa-
rameters indexed to height and body surface area (BSA),
where appropriate [12]. Tissue tracking in the 3 long
axis views was performed offline to assess 2D global lon-
gitudinal strain (GLS), according to previously published
formulae [13]. Analysis of T1 was performed with man-
ual contouring to define a region of interest (ROI)
within the LV myocardium at basal and mid ventricular
level (short-axis) on matched pre- and post-contrast im-
ages within the septum, as well as within the septum in
the horizontal long axis view, and used to calculate myo-
cardial extracellular volume (ECV) by validated formulae
[14]. T1 values were measured in ‘normal myocardium’
defined by the absence of LGE. In addition, both short
axis maps (basal and mid) were also manually contoured
for endo- and epicardial borders, and partial voluming of
blood minimised by using a 20% offset from the endo-
and epicardial border [15]. Stability of T1 measurement
over time was confirmed by weekly analysis of a phan-
tom within the magnet [16]. Analysis of all CMR
parameters was performed by a single observer (SB)
blinded to the identity of the subject, date, and time. A
randomly selected subset of 10 patients were selected for
intra- and inter-observer reproducibility studies by SB
and RV. Bland-Altman plots were used to assess the re-
producibility of these measurements, with mean differ-
ences calculated to identify any bias. Agreement was
further quantified using intraclass correlation coeffi-
cients (ICCs), using two-way random effects models with
absolute agreement.
Phantom studies for T1 stability
T1 times stability over time was assessed using a phan-
tom made of high density plastic beads of agar/nickle
chloride in plastic tubes. High-density polyethylene
macrobeads encased these plastic tubes arranged in a
3 × 3 array, with resin layer at the base. Each tube repre-
sented a range of T1 times. These were scanned regu-
larly for 12 months on a fortnightly basis using the T1
protocol described above. A tight shim was set with all
images acquired at iso-center. The analysis was done
using ROI as described above.
Computed tomographic coronary angiography
Participants without renal dysfunction had a single CT
coronary artery calcium (CAC) score and CTCA per-
formed on dual energy source 64 multi-slice scanner
(Siemens Somaton Definition, Erlangen, Germany) using
retrospective electrocardiogram (ECG) gated acquisition.
A 20mL test bolus of contrast was used to set delay and
80mL of contrast given for final image acquisitions. Sig-
nificant CAD was defined as a lesion > 70% on post-
mortem, invasive or CT coronary angiography.
Statistical methods
The baseline demographics of the cohort were sum-
marised, with continuous variables reported as means ±
standard deviations (SDs) where normally distributed,
and as medians and interquartile ranges (IQRs) other-
wise. Changes over time in a range of markers were then
assessed. Initially, Spearman’s correlation coefficients
(rho) were produced to measure the correlation between
each marker and the timing of the measurement, relative
to each patient’s first scan. However, this approach did
not account for the non-independence of the repeated
scans on each patient. As a result, the analysis was re-
peated using a generalized estimating equation (GEE)
approach. A separate model was produced for each
marker, with the timing of the measurement, relative to
each patient’s first scan as a continuous covariate, and
the patient identification number (ID) as a nominal fac-
tor. The patient ID was set as the subject effect, with the
within-subject effect being the timing of the scan, rela-
tive to the initial scan, rounded to the nearest 6 months.
Baig et al. Orphanet Journal of Rare Diseases          (2020) 15:139 Page 3 of 12
An autoregressive (AR) (1) correlation structure was as-
sumed throughout. Analyses were then performed to as-
sess whether changes over time in T1 corresponded to
changes in other markers. For each marker, separate lin-
ear regression models were produced for each patient
that had data with at least two scans, with the timing of
the measurement relative to baseline, as a covariate. The
gradients from the resulting models were then used to
represent the rate of change in the markers and were
compared using Spearman’s rho correlation coefficients.
In addition, comparisons of gradients across dichotom-
ous variables (e.g. gender) were performed using inde-
pendent samples t-tests. All analyses were performed
using IBM SPSS 22 (IBM Corp. Armonk, NY), with p <
0.05 deemed to be indicative of statistical significance
throughout. For markers that were measured as percent-




There are 38 known adult ALMS patients within the
United Kingdom, of whom 32 regularly attend the special-
ized service in Birmingham. Of these, two were excluded
due to contra-indications to CMR (1 implantable
cardioverter-defibrillator; 1 patient within research study),
hence the analysis was based on the remaining 30. Base-
line demographics and imaging data are presented in
Table 1 and genetic data in Table 2. Family history of pre-
mature CAD was not recorded. The median age at the
first scan was 21.3 years (IQR: 19.0–32.6), 63% of patients
were male and 67% were of White British ethnicity. The
first CMR scan was performed the day before or same day
as the first clinical attendance in the service. From first
CMR, the median follow-up time was 45months (max-
imum 67months), during which time 76 additional scans
were performed, a median of 3 follow-up scans per pa-
tient, with 4 patients only having a single scan during the
follow-up period. More than half the cohort had conven-
tional cardiovascular risk factors (Table 1). At baseline,
LV volumes, ejection fraction (EF) and mass were within
normal limits for age, sex and body surface area on CMR,
although GLS was low-normal and six patients (20%) had
elevated NT-proBNP (≥144 ng/L). In total, 14 patients had
evidence of LGE. Of these, 2 patients had LGE at the in-
sertion of the RV into the basal inferoseptum (insertion
point LGE), 1 had focal subendocardial (mid anteroseptal
LV segment) and 2 had focal epicardial (1 basal and mid
inferolateral; 1 mid inferior and mid inferolateral LV seg-
ments) LGE. Mid wall LGE was present in 5 patients lo-
cated within the basal and mid inferolateral LV segments,
while 4 patients had extensive LV and RV LGE. The LGE
pattern did not correspond to a specific coronary artery
disease distribution.




Age at first scan (years) 30 21 (19–33)
Male Gender (%) 30 19 (63%)
White British (%) 30 20 (67%)
BMI (kg/m2) 30 29 (26–32)
Systolic BP (mmHg) 30 130 ± 19
Diastolic BP (mmHg) 30 82 ± 12
Heart rate (beats/min) 30 86 ± 17
CMR
T1 Basal (ms) 30 937 (913–1030)
T1 SAX Basal ECV (%) 30 27 (22–33)
LVEDVi (mL/m2) 30 58 ± 12
LVEF (%) 30 64 ± 9
LV mass index (g/m2) 30 55 (51–61)
LAV index (mL/m2) 30 34 (25–43)
GLS (%) 30 16 ± 3
Echocardiogram
E/A ratio 29 1.5 (1.3–1.6)
Average E/e’ ratio 30 7.4 ± 2.1
e’ ave. (cm/s) 27 9.1 (7.7–11.0)
Blood markers
Haemoglobin (g/dL) 30 14.0 ± 2.3
HbA1c (mmol/mol) 29 49 (39–71)
C-peptide (pmol/L) 30 3136 (1516–4113)
Cholesterol (mmol/L) 30 4.8 ± 1.3
Triglycerides (mmol/L) 30 2.5 (1.7–4.2)
NT-proBNP (ng/L) 30 51 (25–93)
eGFR (mL/min/1.73 m2) 30 108 (62–123)
Comorbidities
Hypertension 30 17 (57%)
Dyslipidaemia 30 18 (60%)
Infantile cardiomyopathy 30 12 (40%)
Diabetes 30 18 (60%)
CKD 30 18 (60%)
BMI indicates body mass index, BP blood pressure, CMR cardiovascular
magnetic resonance, E/A ratio mitral early filling (E)/atrial filling (A) ratio, E/e’
mitral early filling (E)/early myocardial relaxation velocity (e’), ECV extracellular
volume, eGFR estimated glomerular filtration rate, GLS global longitudinal
strain, HbA1c glycated haemoglobin A1c, IQR interquartile range, LAV left atrial
volume, LV left ventricular, LVEDVi left ventricular end-diastolic volume
indexed to body surface area, LVEF left ventricular ejection fraction, LVESVi left
ventricular end-systolic volume indexed, NT-proBNP serum Nterminal pro B
natriuretic peptide, RV right ventricle, SAX short axis, CKD chronic
kidney disease
Data are reported as N (%), mean ± SD, or median (IQR), as applicable
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Serial data
On correlation analysis, T1 basal and mid ventricular level
(short-axis; both p < 0.001), ECV basal and mid ventricular
level (short-axis; p = 0.081 and p = 0.064), and LV mass
(p = 0.008) all increased over time. Analysis of serial mea-
surements using a GEE approach found significant in-
creases over time in T1, as measured on the basal and mid
ventricular (short-axis) levels, with similar gradients of
25.8ms per year (95% CI: 20.0–31.7, p < 0.001) and 21.8
ms per year (95% CI: 17.4–26.1, p < 0.001), respectively
(Fig. 1a). Significant increases in ECV were also observed,
with gradients of 1.4 percentage points per year (95% CI:
0.8–2.0, p < 0.001) and 1.1 percentage points per year
(95% CI: 0.6–1.6, p < 0.001) for basal and mid ventricular
levels, respectively (Fig. 1b). Figure 2 shows an example of
changes in T1 for a specific individual. In addition, the LV
mass index was found to increase significantly over time,
by an average of 2.8 g/m2 per year (95% CI: 1.9–3.7 g/m2,
p < 0.001). Analyses using a correlation approach returned
consistent findings (Table 3).
Table 2 Mutations in ALMS1 gene in study participants












Nonsense 8 c.2041C > T p.Arg681*X Homo ?Nonsense 8 c.2041C > T p.Arg681*
Nonsense 8 c.6823C > T p.Arg2275* CH Nonsense 10 c.9535C > T p.Arg3179*
Nonsense 8 c.2822 T > A p.Leu941* CH Frameshift 16 c.10775delC p.Thr3592Lysfs*6
Frameshift 8 c.6584delA p.Lys2195Serf*10 CH Nonsense 5 c.1008_1009delTG p.Cys336fs*1
Nonsense 10 c.8002C > T p.Arg2668* CH Nonsense 16 c.10879C > T pArg3627*
Nonsense 10 c.9001C > T p.Gln3001* Hetero
Frameshift 8 c.6895delG p.val2299Trps*43 CH Frameshift 16 c.11443C > T p.Gln3815*
Nonsense 16 11107C > T p.Arg3703* Hetero
Nonsense 16 11107C > T p.Arg3703* Homo Nonsense 16 11107C > T p.Arg3703*
Frameshift 16 c.10579_1580delAT p.Met3527Valfs*13 CH Frameshift 18 c.11856delC p.Asn3952Lysfs*41
Frameshift 16 c.10769delC p.Thr3590Lysfs*6 CH Missense 8 c.5356A > G p.Asn1786Asp
Nonsense 16 c.11107C > T p.Arg3703* Hetero
Nonsense 8 c.6823C > T p.Arg2275* CH Nonsense 10 c.9535C > T p.Arg3179*
Frameshift 8 c.1729delA p.Arg577Glyfs*17 CH Nonsense 16 c.10477C > T p.Gln3493*
8 c6526C > T p.Gln217* Hetero
Nonsense 10 c.8932C > T p.Gln2978* CH Missense 8 c.5356A > G p.Asn1786Asp
Nonsense 8 c.4937C > A p.Ser1646* Homo Nonsense 8 c.4937C > A p.Ser1646*
Nonsense 8 c.4937C > A p.Ser1646* Homo Nonsense 8 c.4937C > A p.Ser1646*
9 c.7544- Homo Exon 9 c.7544-
Deletion 200_7677 + 1110del deletion 200_7677 + 1110del
Nonsense 8 c.4937C > A p.Ser2646* Hetero Nonsense 8 c.6526C > T p.Gln2176*
Nonsense 8 c.6299C > A p.Ser2100* CH Nonsense 16 c.10477C > T p.GIn3493*
Nonsense 8 c.6299C > A p.Ser2100* CH Nonsense 16 c.10477C > T p.GIn3493*
Frameshift 16 c.10769delC p.Thr3590Lysfs*6 CH Missense 16 c.11410C > T p.Arg38404*
Exon 9 c.7544- Homo Exon 9 c.7544-
deletion 200_7677 + 1110del deletion 200_7677 + 1110del
Nonsense 8 c.2041C > T p.Arg681* Homo Nonsense 8 c.2041C > T p.Arg681*
Nonsense 8 c.2041C > T p.Arg681* Homo ?Nonsense 8 c.2041C > T p.Arg681*
Exon deletion 9 c.7544- Homo Exon deletion 9 c.7544- 200_7677
+ 1110del
Nonsense 16 200_7677 + 1110del p.Gln3495* CH Frameshift 16 c.10775delC p.Thr3592Lysfs*6
Nonsense 16 11107C > T p.Arg3703* Hetero
Frameshift 10 c.7911dupC p.Asn2638Glnfs*24 Homo Frameshift 10 c.7911dupC p.Asn2638Glnfs*24
CH indicates compound heterozygote, Hetero, Heterozygote; Homo, homozygote
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Two patients developed LGE during follow up, 1 of
whom developed new RV insertion point LGE and 1
developed subendocardial LGE in the mid anterosep-
tum (participants 10 & 11). No significant changes over
time were detected in LV end-diastolic volume indexed
to BSA (LVEDVi, p = 0.909), LV end-systolic volume
indexed to BSA (LVESVi, p = 0.067), LV ejection frac-
tion (EF, p = 0.575), left atrial volume indexed (LAVi,
p = 0.409), or LV GLS (GLS, p = 0.809). In addition, no
significant changes over time were noted in diastolic
function on echocardiography, including mitral early
filling (E)/atrial filling (A) ratio (p = 0.313), and average
E/early myocardial relaxation velocity (e’, p = 0.299)
(Table 3).
Factors associated with change in ECV or T1
Changes in ECV and T1 were not found to be signifi-
cantly associated with differences in LV volumes, mass,
or EF over follow-up (Table 4). Although there was a
significant association between increasing T1 and im-
paired (less negative) GLS (Rho 0.422, p = 0.036, this re-
lationship was not mirrored by increasing ECV.
Moreover, there was also no evidence of a significant as-
sociation between the change in ECV or T1 and markers
of diastolic function (E/A; E/e’ average; LAV). There was
no evidence of a significant relationship between change
in ECV or T1 with age, hypertension, diabetes, history of
infantile cardiomyopathy, or presence/absence of coron-
ary artery disease (CAD) (Table 5).
Fig. 1 Serial Change Over Time
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Coronary artery disease
Presence or absence of CAD could not be established in
3 of the 30 patients. One patient was not assessed, as
they refused to undergo CAC/CTCA due to a combin-
ation of claustrophobia and needle phobia, while 2 pa-
tients had not undergone CAD assessment at time of
data collection. Of the remaining 27 patients, 3 patients
presented with symptoms and were diagnosed with
CAD. Of these, one died before a CTCA could be per-
formed, but post-mortem showed a right coronary artery
occluded with thrombus. The second patient had inva-
sive coronary angiography following onset of symptoms
and was found to have severe CAD. The third patient
has CAD (> 70% stenosis in the mid left anterior de-
scending artery) identified on CTCA and was treated by
percutaneous coronary intervention with stent implant-
ation. The remaining 24 asymptomatic patients all had a
CTCA done, and 22 had CAC scoring. Of these, 4 were
found to have elevated CAC Agatston scores of 48, 69,
156, and 209. These 4 patients were found to have mild
atheroma with no flow-limiting stenosis, with CTCA be-
ing normal in the remainder. In summary, a total of 3/
27 (11%) had significant CAD defined by > 70% stenosis,
whilst a further 4/27 (15%) had non flow-limiting ather-
oma. Further details about these 7 patients are reported
in Table 6.
Intra- and inter-observer reproducibility, phantom study
and Normal ranges
Ten CMR studies were randomly selected for assessment
of intra- and inter-observer variation. There was no con-
sistent pattern of inter-observer bias on Bland-Altman
analyses. Intra-observer mean bias for basal T1 was 5.8
ms (95% CI -4.3, 15.8 ms), with an ICC (random model)
of 0.9 (p < 0.001), whilst inter-observer mean bias for
basal T1 was 6.4 ms (95% CI − 7.2, 20 ms), with an ICC
of (0.9, p < 0.001). Normal T1 measurements and ECV
values using the same protocol in normal volunteers on
the same scanner were as follows: (n = 26) mid short axis
(SAX) pre contrast T1 970 ± 11ms; post contrast T1
Fig. 2 Changes in T1 Mapping Over Time Within an Individual. a Mid SAX T1 map at baseline (patient 1) b Mid SAX T1 map at 4 years (patient 1).
c Modified SAX T1 map at baseline. d Modified SAX T1 map at 4 years. a represents T1 maps at baseline (T1 in ROI 923 ms) and b represent the
increase T1 times at 4 years (T1 in ROI 1012ms). The modified T1 maps (c & d) of the original maps (a & b) have been colour coded to show the
difference. The scale represents an increase in T1 toward the top. SAX, short axis slice
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522 ± 58 ms; ECV 25 ± 1%. Over 12 months, 25 MOLLI
datasets were collected. The scanner room temperature
was stable at 20.96 + 0.98 C. Coefficients of variation
across the 9 tubes were stable and ranged from 0.436 to
0.872% when unadjusted for temperature and improved
to and 0.436 to 0.868% with correction for room
temperature.
Discussion
This is the first prospective study to demonstrate an in-
crease in T1 and ECV over time, paralleled by an in-
crease in LV mass in ALMS. Despite changes in T1 and
ECV, there was no association with serial changes in sys-
tolic or diastolic contractile dysfunction, either in terms
of EF, E/A, E/e’, LA volume, or elevation in biomarker
(NT-proBNP). Although increasing native T1 over time
was associated with impaired (less negative) GLS, this
was an isolated relationship that was not mirrored in re-
lation to ECV and was not associated with other changes
in functional parameters, The increased T1 and ECV
were not significantly associated with the presence or
absence of CAD. These data are consistent with mild,
progressive myocardial fibrosis over time in ALMS, al-
though no structural or consistent functional conse-
quences were noted within a median three and a half
years’ follow up. Why is this finding of importance?
ALMS is characterized by obesity, insulin resistance and
dyslipidaemia, diseases that are common but are





Correlation Analysis GEE Analysis
Rho p-Value Gradient (95% CI) p-Value
T1 SAX Basal (ms) 30 104 0.415 < 0.001 25.8 (20.0, 31.7) < 0.001
T1 SAX Mid (ms) 30 104 0.451 < 0.001 21.8 (17.4, 26.1) < 0.001
T1 SAX Basal ECV (%, pp) 30 94 0.181 0.081 1.4 (0.8, 2) < 0.001
T1 SAX Mid ECV (%, pp) 30 94 0.192 0.064 1.1 (0.6, 1.6) < 0.001
LVEDV Index (ml/m2) 30 106 −0.113 0.247 0.04 (−0.60, 0.68) 0.909
LVESV Index (ml/m2) 30 106 −0.164 0.094 0.92 (−0.06, 1.90) 0.067
LVEF (%, pp) 30 106 0.104 0.289 −0.27 (−1.23, 0.68) 0.575
LV Mass Index (g/m2) 30 104 0.257 0.008 2.8 (1.9, 3.7) < 0.001
LAV Biplane (ml/m2) 29 60 −0.221 0.090 −2.0 (−6.7, 2.7) 0.409
GLS 30 95 0.032 0.756 − 0.04 (− 0.33, 0.26) 0.809
GRS 28 86 0.010 0.924 −0.36 (−1.18, 0.47) 0.394
E/A 29 72 0.133 0.267 2.3 (−2.2, 6.9) 0.313
E/e’ Average 30 68 0.161 0.189 0.3 (−0.2, 0.8) 0.299
HBA1c (mmol/mol) 29 100 − 0.116 0.250 −0.9 (−2.5, 0.7) 0.284
C-Peptide (pmol/L) 30 94 −0.028 0.788 −90.7 (− 364.6, 183.2) 0.516
NTpro BNP (ng/L) 30 105 −0.101 0.306 34.4 (−33.9, 102.8) 0.324
Correlation analysis – results are from Spearman’s rho correlation coefficients between the marker and the timing of the scan, relative to the baseline scan
GEE analysis - results are from generalised estimating equation models, as described in the methods. The “gradient” represents the average yearly change in the
marker over the period
Bold p-values are significant at p < 0.05. ECV and EF were measured as percentages, hence gradients represent percentage point (pp) increases
E/A mitral early filling (E)/atrial filling (A), E/e’, mitral early filling (E)/early myocardial relaxation velocity (e’), ECV extracellular volume, HbA1c glycated haemoglobin
A1c, LAV left atrial volume, LV left ventricular, LVEDV index, left ventricular end-diastolic volume indexed to body surface area, LVEF left ventricular ejection
fraction, LVESV index, left ventricular end-systolic volume indexed, NT-proBNP serum Nterminal pro B natriuretic peptide; SAX, short axis
Table 4 Associations Between T1/ECV Over Time and Changes
in Myocardial Structure and Function
Gradient in T1 SAX Mid
Gradient
T1 SAX Mid ECV
Gradient
N Rho p-Value N Rho p-Value
LVEDV Index (ml/m2) 26 0.019 0.927 24 −0.052 0.809
LVESV Index (ml/m2) 26 −0.444 0.023 24 −0.188 0.379
LVEF (%) 24 0.352 0.091 22 0.088 0.699
LV Mass Index (g/m2) 26 −0.056 0.784 24 0.203 0.340
LAV Biplane (ml/m2) 20 0.245 0.298 18 −0.377 0.123
GLS 25 0.422 0.036 23 0.024 0.914
GRS 23 0.268 0.217 21 0.116 0.618
E/A 22 −0.292 0.187 20 −0.029 0.905
E/e’ Average 23 −0.370 0.083 21 −0.268 0.241
HBA1c (mmol/mol) 24 −0.119 0.579 22 0.189 0.399
C-Peptide (pmol/L) 26 −0.101 0.624 24 −0.037 0.865
Pro NT BNP (ng/L) 26 −0.072 0.726 24 0.023 0.913
For each of the markers considered, a linear regression model was produced
for each patient, with the timing of the scan, relative to the first scan, set as a
continuous covariate. Only those patients with at least two valid scans for the
stated marker were included in the analysis. Spearman’s (rho) correlation
coefficients were then produced between the resulting gradients. Bold p-
values are significant at p < 0.05
E/A mitral early filling (E)/atrial filling (A), E/e’, mitral early filling (E)/early
myocardial relaxation velocity (e’), ECV extracellular volume, HbA1c glycated
haemoglobin A1c, LAV left atrial volume, LV left ventricular, LVEDV index left
ventricular end-diastolic volume indexed to body surface area, LVEF, left
ventricular ejection fraction; LVESV index, left ventricular end-systolic volume
indexed; NT-proBNP, serum Nterminal pro B natriuretic peptide; SAX, short axis
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projected to increase beyond that expected by evolving
population demographics [17]. Furthermore, heart fail-
ure is highly prevalent in each, with adverse prognosis
whether or not associated with coronary artery disease
[18]. Given the premature onset of cardiomyopathy,
ALMS is a paradigm to investigate the role of DIF in
pathogenesis of heart failure, and whether this may be a
target for therapeutic intervention [19] or simply a by-
stander to other disease processes [20]. In such a popu-
lation, particularly one with a high rate of hypertension
at baseline, it is of interest that while indexed LV mass
increased, there was no relationship with change in T1
or ECV. Our data identifies progression of DIF that is
independent of coronary artery disease, but further
Table 5 Association between baseline factors and changes in T1/ECV
T1 SAX Mid Gradient (ms per Year) T1 SAX Mid ECV Gradient (pp per Year)
N Mean ± SD p-Value N Mean ± SD p-Value
Age at First Scan* 26 −0.137* 0.505* 24 0.169 0.430
Ethnicity 0.278 0.360
White British 18 26.3 ± 25.2 17 1.8 ± 2.5
Other 8 12.7 ± 35.9 7 0.7 ± 2.6
Gender 0.112 0.864
Male 17 15.5 ± 29.4 15 1.4 ± 2.5
Female 9 34.5 ± 24.8 9 1.6 ± 2.8
ACE/ARB 0.969 0.771
No 6 21.7 ± 56.6 5 1.8 ± 2.9
Yes 20 22.2 ± 16.0 19 1.4 ± 2.5
Statins/Fibrates 0.103 0.121
No 14 30.7 ± 22.5 14 2.1 ± 2.8
Yes 12 12.1 ± 33.1 10 0.5 ± 1.7
Hypertension 0.930 0.117
No 11 21.5 ± 35.6 10 0.5 ± 2.4
Yes 15 22.5 ± 24.2 14 2.1 ± 2.4
Hyperlipidaemia 0.040 0.989
No 11 35.5 ± 21.8 11 1.5 ± 2.2
Yes 15 12.3 ± 30.1 13 1.5 ± 2.8
Infantile cardiomyopathy 0.710 0.904
No 16 20.4 ± 33.0 15 1.5 ± 2.9
Yes 10 24.9 ± 22.0 9 1.4 ± 1.9
Diabetes 0.764 0.132
No 9 19.7 ± 39.3 9 0.5 ± 2.5
Yes 17 23.4 ± 23.0 15 2.1 ± 2.4
Insulin resistance (not diabetes) 0.752 0.870
No 20 21.1 ± 30.2 18 1.5 ± 2.6
Yes 6 25.5 ± 26.3 6 1.3 ± 2.4
CKD 0.889 0.630
No 12 23.0 ± 33.3 12 1.2 ± 2.0
Yes 14 21.4 ± 25.8 12 1.7 ± 3.0
Presence of CAD** 0.622 0.121
No 20 23.5 ± 27.5 20 1.0 ± 2.0
Yes 3 32.7 ± 44.7 3 3.4 ± 4.7
Gradients were calculated on a per-patient basis, as described in the methods, with the resulting values reported as mean ± SD, and compared between groups
using independent samples t-tests, unless stated otherwise. Only those patients with at least two valid scans for the stated marker were included in the analysis
*Reported as a Spearman’s rho correlation coefficient and p-value. **Excludes N = 3 patients with unknown CAD status. Note that ECV was measured as a
percentage, hence gradients are reported in percentage points (pp) per year. Bold p-values are significant at p < 0.05
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research is needed to clarify relationship with functional
decline.
Previous studies have demonstrated that T1 values
and ECV are increased in ALMS compared to control
subjects [3, 4]. These data are consistent with post-
mortem histology studies demonstrating both coarse
and DIF in adults with ALMS [1, 21, 22]. Although the
data correlating high T1, increased ECV, and histology
in ALMS are limited [4], T1 mapping and ECV on CMR
as markers of DIF have been validated histologically in
other conditions [23–25]. Longitudinal studies have
shown T1 mapping to be a robust parameter, with little
variability in healthy individuals over time, and in our
study, the increase was measured in a single magnet
using the same sequence with stable signal confirmed by
phantom [26]. The increase in T1 and ECV was not,
however, associated with a change in systolic or diastolic
contractility, other than an isolated association between
native T1 and GLS, measured either by CMR or echo-
cardiography. In our previous cross-sectional study, an
association was found between increased T1 and ECV
and altered GLS measured using CMR tagging, and it
may be that the method used in this serial study, tissue-
tracking, was less sensitive [4]. It is also notable that in
our previous and current work, a significant proportion
of the ALMS population have both native T1 and ECV
within normal range. In fact, baseline values in the
current study for both native T1 and ECV were below
the reference values for normal subjects, an effect which
is usually attributable either to deposition of lipid or ac-
cumulation of iron, neither of which have been de-
scribed in the limited histological data in adults with
ALMS. Furthermore, the size of the change was small
and it is possible either that change in function may re-
quire longer follow-up to have a significant impact, or
that progression of fibrosis may be variable between in-
dividuals. This is consistent with lack of functional
change on serial CMR over 2 years seen in patients with
chronic stable cardiomyopathy who had a detectable in-
crease in T1 times [27]. Given the potential signal of an
association between increasing native T1 and impaired
GLS, further prospective studies are needed to see if the
increased T1 and ECV are associated in the longer term
with the development of systolic dysfunction, heart fail-
ure and death, as has been demonstrated in other popu-
lations [28–31].
Infantile cardiomyopathy is a common finding in in-
fants with ALMS, presenting within the first 3 months of
life [32]. The majority (74%) survive, with response to
standard heart failure therapy resulting in recovery of
cardiac function in the majority [2]. Recent evidence
suggests that the ALMS1 protein has a role in perinatal
cardiomyocyte cell division and replication, and that its
deficiency can cause mitogenic cardiomyopathy [33, 34].
The mechanisms leading to infantile cardiomyopathy ap-
pear to differ from those seen in adult cardiomyopathy,
where myocardial fibrosis plays a dominant role. In
keeping with this, there was no detectable difference in
structure, function, or progression of T1/ECV between
those patients with and those without a history of infant-
ile disease. In addition, given the risk profile of the
ALMS cohort under care, it was thought important to
investigate the potential impact of CAD on the develop-
ment of myocardial fibrosis and heart failure. More than
Table 6 Details of Seven Patients with Coronary Artery Disease or Coronary Artery Atheroma
Patient ID 1 2 3 4 5 6 7
Age 38 42 19 48 36 43 19
Gender M M M M M F M
Agatston PM ICA 1 48 69 156 209




Mild atheroma LAD stenosis
LGE Pattern Extensive diffuse Focal epicardial Mid wall
LGE




LGE territory Basal infero-lateral
segment, basal, mid























HTN Y Y Y Y Y Y N
Hyperlipidaemia Y Y Y Y Y Y Y
Diabetes Y Y IR Y N N Y
CKD Stage 2 5 0 2 1 1 2
Infantile CM N Y N N Y Y Y
ICA invasive coronary angiography, CKD chronic kidney disease stage, CM cardiomyopathy, HTN hypertension, ID identification number, LAD left anterior
descending, PM Post mortem finding, N no, Y yes
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a quarter of the cohort (7/27) had evidence of coronary
atheroma, although only 3 patients had flow-limiting dis-
ease, 2 of whom were symptomatic. The prevalence of
CAD was not found to influence the progression of T1
or ECV significantly in this study, although the statistical
power of this analysis was low due to small numbers.
Limitations. The primary limitation of this study, inev-
itably, is the relatively small sample size. As a result of
this, the statistical power of analyses is low, meaning
that only relatively large effects would have been
detecteable, increasing the risk of false negatives. This
was especially applicable to the analyses comparing the
T1 and ECV gradients across baseline factors, particu-
larly for comparisons across groups with unequal num-
bers of patients, such as the presence of CAD (N = 3 vs.
N = 20). Although numbers were small, participants had
a genetically confirmed rare disease, recruited from a na-
tional centre with one of the largest adult cohorts avail-
able. Where significant trends over time were detected,
the rates of change were generally small, and may not
have been sufficient to have clinical impact in the short-
term. However, the fact that the trajectories were similar
across the whole cohort, and that testing of the scanner
using a phantom within the magnet used demonstrated
marked stability of the signal over time, would suggest
that these trends are reflective of genuine progression of
fibrosis. Further research is needed in a larger cohort,
which is likely to require organisation of an international
registry.
Baseline T1 values were heterogeneous in our cohort,
consistent with our previous and other research in
ALMS [3], although this may in part be accounted for
differences in age, gender and co-existing metabolic sta-
tus. This significant inter-individual variation suggests
that development of fibrosis is not an inevitable conse-
quence of the genetic defect alone and that environmen-
tal factors may also play an important role. We
acknowledge however, the possibility of myocardial fat
deposition or pseudo normalization of T1 due to the
combined presence of lipid and fibrosis within the LV.
Our own limited post-mortem data did not identify sig-
nificant myocardial fat deposition in ALMS but recog-
nise that further tissue characterisation, including T2
mapping, would have been enlightening. It is also im-
portant to note that distribution of mid wall LGE has a
predilection for the inferolateral wall, which is seen in a
number of different diseases, but is not limited to that
location, as in early male Fabry disease, which is consist-
ent with our hypothesis that fibrosis is not inevitable but
may be subject to individual and environmental factors.
Conclusion
This is the first comprehensive longitudinal study to
suggest that myocardial fibrosis in ALMS progresses
over time. There were no associated functional changes
in systolic or diastolic function over follow-up, suggest-
ing that these occur later in the natural history of ALMS
cardiomyopathy. Longer term studies should be per-
formed to confirm whether the development of DIF over
time may be the primary driver rather than a conse-
quence of ventricular dysfunction and heart failure.
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